Alaunos Therapeutics (TCRT) Assets Average (2010 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Assets Average came in at $2.4 million in Q1 2026, down 0.53% YoY from $2.4 million in Q1 2025, and down 27.52% on a QoQ basis from $3.3 million in Q4 2025.
Alaunos Therapeutics (TCRT) Assets Average (2010 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 17 years of Assets Average data on file, last reported at $2.4 million in Q1 2026.
- Quarterly Assets Average fell 0.53% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 0.53% YoY) and the FY2025 annual result came in at $2.9 million, down 48.08% from the prior year.
- Assets Average fell to $2.4 million in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $89.9 million in Q1 2022 to a low of $2.4 million in Q1 2026.
- A 5-year average of $27.9 million and a median of $7.2 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average sank 87.41% — and 2025, when it increased 6.11%.
- Tracing TCRT's Assets Average over 5 years: stood at $66.1 million in 2022, then sank by 79.06% to $13.9 million in 2023, then slumped by 77.24% to $3.2 million in 2024, then advanced by 6.11% to $3.3 million in 2025, then slipped by 27.52% to $2.4 million in 2026.
- The last three Assets Average figures came in at $2.4 million (Q1 2026), $3.3 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 19.82 Bn |
| 10 | Alaunos Therapeutics | 4.22 Mn | 4.10 Mn | - | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | 3.35 Mn |
| Sep 30, 2025 | 4.23 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Dec 31, 2024 | 3.15 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | 5.36 Mn |
| Mar 31, 2024 | 7.15 Mn |
| Dec 31, 2023 | 13.85 Mn |
| Sep 30, 2023 | 23.68 Mn |
| Jun 30, 2023 | 38.28 Mn |
| Mar 31, 2023 | 56.79 Mn |
| Dec 31, 2022 | 66.14 Mn |
| Sep 30, 2022 | 70.64 Mn |
| Jun 30, 2022 | 79.46 Mn |
| Mar 31, 2022 | 89.93 Mn |
| Dec 31, 2021 | 104.31 Mn |
| Sep 30, 2021 | 110.26 Mn |
| Jun 30, 2021 | 117.62 Mn |